"Globally Renowned for Expertise in Liver Care and Research TLI is a one-of-a-kind facility that encompasses one of the few dedicated and freestanding clinic (Texas Liver Consultants, TLC) and research facilities (American Research Corporation, ARC). The most advanced research in viral hepatitis, alcoholic and non-alcoholic fatty liver disease, autoimmune liver disease, and cirrhosis is conducted at this facility, which has been recognized internationally for its contributions to the field of liver diseases."

During the past decade, American Research Corporation at the Texas Liver Institute conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 23 clinical trials were completed, i.e. on average, 39% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 19 clinical trials were completed. i.e. 59.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "American Research Corporation at the Texas Liver Institute" #1 sponsor was "Gilead Sciences" with 12 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "CymaBay Therapeutics, Inc." with 5 trials sponsored, "Intercept Pharmaceuticals" with 5 trials sponsored and "Enanta Pharmaceuticals, Inc" with 5 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "American Research Corporation at the Texas Liver Institute" #1 collaborator was "Novo Nordisk A/S" with 2 trials as a collaborator, "DSM Nutritional Products, Inc." with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Pharmaceutical Research Associates" with 1 trials as a collaborator and "Triangle Biostatistics" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "American Research Corporation at the Texas Liver Institute" are "Nonalcoholic Steatohepatitis" (9 trials), "Primary Biliary Cholangitis" (5 trials), "Hepatic Impairment" (4 trials), "Healthy" (3 trials) and "Liver Diseases" (3 trials). Many other conditions were trialed in "American Research Corporation at the Texas Liver Institute" in a lesser frequency.

Most popular intervention types in "American Research Corporation at the Texas Liver Institute" are "Drug" (58 trials), "Other" (2 trials), "Biological" (1 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "SEL" (5 trials), "BI 685509" (3 trials), "BI 456906" (2 trials) and "CILO" (2 trials). Other intervention names were less common.

The vast majority of trials in "American Research Corporation at the Texas Liver Institute" are 57 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "American Research Corporation at the Texas Liver Institute". undefined are not yet recruiting, 15 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in American Research Corporation at the Texas Liver Institute, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in American Research Corporation at the Texas Liver Institute, 9 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".